Business Parks & Science Centres

 
 
 

Advertisement

Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 273x168px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements from Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 5658 | Ordered by Date (descending)
next pagenext page 1 2 3 ... 17 18 19 ... 55 56 57  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
PharmGenomics (DE)–SEVERAL: investment, 201601 financing round incl ISB + KfW + private investors 2016-01-20
Abviris–High-Tech Gründerfonds: investment, 201601 financing round mid six-digit € figure from HTGF + MBG Schleswig-Holstein 2016-01-19
Abviris–Schleswig-Holstein (govt): investment, 201601 financing round mid six-digit € figure from HTGF + MBG Schleswig-Holstein 2016-01-19
Abviris–SEVERAL: investment, 201601 financing round mid six-digit € figure from HTGF + MBG Schleswig-Holstein 2016-01-19
Zespri–Metabolomic Discoveries: metabolomic services, 201601– supply service MS-based profiling of kiwi fruit using Flavour Profiler Technology 2016-01-18
Emerald Cleantech–Evonik: investment, 201601 existent investment in Emerald Cleantech Fund III by Evonik Venturing 2016-01-15
GRC SinoGreen–Evonik: investment, 201601 investment €na in GRC SinoGreen Fund III by Evonik Venturing 2016-01-15
Pangaea Ventures–Evonik: investment, 201601 existent investment in Pangaea Ventures Fund III by Evonik Venturing 2016-01-15
Ayoxxa–Germany (govt): business development, 201601– supply service support in US with German Accelerator Life Sciences programme 2016-01-13
Pepperprint–Germany (govt): business development, 201601– supply service support in US with German Accelerator Life Sciences programme 2016-01-13
Personal MedSystems–Germany (govt): business development, 201601– supply service support in US with German Accelerator Life Sciences programme 2016-01-13
Sonormed–Germany (govt): business development, 201601– supply service support in US with German Accelerator Life Sciences programme 2016-01-13
HRTBT Medical Solutions–DocCheck: investment, 201601 financing round high 6-figure € sum from HTGF + DockCheck Guano 2016-01-12
HRTBT Medical Solutions–High-Tech Gründerfonds: investment, 201601 financing round high 6-figure € sum from HTGF + DockCheck Guano 2016-01-12
HRTBT Medical Solutions–SEVERAL: investment, 201601 financing round high 6-figure € sum from HTGF + DockCheck Guano 2016-01-12
AB2 Bio–SEVERAL: investment, 201601 financing round Series B CHF21m ($21m) from existent + new investors 2016-01-11
AbVitro–Juno Therapeutics: investment, 201601 acquisition $78m in cash + 1.289m shares of Juno stock 2016-01-11
Array BioPharma–Qiagen: molecular companion diagnostics, 201601– collab master agreement developm + commercialisation of CDx for drugs 2016-01-11
Nestlé–Seres Therapeutics: microbiome-based drug, 201601– ww rights excl North America to SER-109+SER-262+SER-287 $120m upfront 2016-01-11
Novartis–Surface Oncology: cancer immunotherapy, 201601– collab + license up to $170m in upfront + equity + milestones for 4 pre-clinical programs 2016-01-11
Novimmune–SEVERAL: investment, 201601 financing round CHF30m from existing shareholders 2016-01-11
Tensha Therapeutics–Roche: investment, 201601– acquisition $115m upfront cash + $420m milestones 2016-01-11
Affymetrix–Thermo Fisher: investment, 201601–201603 acquisition of Affymetrix for $1.3b in cash 2016-01-08
Amgen–Biocartis: molecular companion diagnostics, 201712– collab €na developm liquid biopsy Idylla RAS CDx test for Vectibix 2016-01-07
C4 Therapeutics–Roche: investment, 201601 financing round Series A totalling $73m incl lead investor Cobro Ventures + co-investor Roche 2016-01-07
C4 Therapeutics–SEVERAL: investment, 201601 financing round Series A $73m led by Cobro plus Cormorant + Kraft Group + EG Capital + Roche + Novartis 2016-01-07
Merck (DE)–Biocartis: molecular companion diagnostics, 201601– collab developm liquid biopsy Idylla RAS test RUO for mCRC 2016-01-07
Roche–C4 Therapeutics: drug discovery, 201601– collab up to >750m developm TPD therapeutics against Roche targets using Degronimid platform 2016-01-07
Biogen–Rodin Therapeutics: CNS drugs, 201601– collab multi-year around neural epigenetics incl investment by Biogen 2016-01-06
Rodin Therapeutics–SEVERAL: investment, 201601– preferred stock financing commitments totalling $17.3m from Altas Venture + Biogen 2016-01-06
BRAIN–MIG Fonds: investment, 201601 existent shareholding of 20% by MIG 2016-01-05
BRAIN–Oddo: investment banking, 201601– supply service Oddo Seydler is lead manager for IPO of BRAIN at FSE 2016-01-05
BRAIN–Putsch (Recaro): investment, 201601 existent shareholding of 51% by MP Betiligungs GmbH 2016-01-05
BRAIN–SEVERAL: investment, 201601–201602 IPO €32.5m net €31.5m w 3.5m+108k shares at €9/share at Frankfurt Stock Exchange 2016-01-05
Scholar Rock–SEVERAL: investment, 201601 financing round Series B $36m 2016-01-04
Famille Michaud Apiculteurs–Bruker Corp: NMR FoodScreener, 201601– supply use of Honey-Profiling module of NMR FoodScreener for QC of honey 2016-01-01
Mecuris–Bavaria (govt): investment, 2016c seed financing round from Bayern Kapital + HTGF 2016-01-01
Mecuris–High-Tech Gründerfonds: investment, 2016c seed financing round from Bayern Kapital + HTGF 2016-01-01
Mecuris–SEVERAL: investment, 2016c seed financing round from Bayern Kapital + HTGF 2016-01-01
Merus–Minapharm: GlymaxX technology, 2016– non-excl license agreem for use of GlymaxX for Biclonics pipeline from ProBioGen AG 2016-01-01
MicrobeDx–Microfluidic ChipShop: microfluidics technology, 2016– collab developm + production of pharmacodiagnostic test systems 2016-01-01
Probiodrug–Crossbeta Biosciences: biomarker research, 2016– collab developm Alzheimer biomarker to support Probiodrug’s clinical AD program 2016-01-01
Roche–Max Planck: drug discovery services, 201601–20812 collab LDC will act as translational incubator for small molecule projects w academic partners 2016-01-01
Storm Therapeutics–Evotec: drug discovery services, 2016– supply service HTS + structural biology to identify hits for 2 RNA modulating targets 2016-01-01
UCB–Evotec: compound management, 201601–202012 supply service €na sample management for UCB by Evotec Toulouse 2016-01-01
Mo Bio Laboratories–Qiagen: investment, 2015Q4 acquisition by Qiagen 2015-12-31
Mologen–Bâloise: investment, 201512 existing investor Bâloise Holding holding estimated 6% in Mologen 2015-12-31
Mologen–Deutsche Balaton: investment, 201512 existing investor holding estimated 5% in Mologen 2015-12-31
Mologen–Global Derivative Trading: investment, 201512 existing investor Global Derivative Trading GmbH owns estimated 24% in Mologen 2015-12-31
Mologen–Salvator Vermögensverwaltungs GmbH: investment, 201512 existing investor holding estimated 5% in Mologen 2015-12-31
Mologen–Signal Iduna: investment, 201512 existing investor Deutscher Ring Krankenversicherung holding estimated 6% in Mologen 2015-12-31
Boehringer–Polyphor: drug discovery, 201512 collab existent to identify + optimise drug candidates using macrocycle platform 2015-12-22
Effector Therapeutics–Abingworth: investment, 201512 financing round Series B totalling $40m incl returning investor Abingworth 2015-12-22
Effector Therapeutics–GSK: investment, 201512 financing round Series B totalling $40m incl returning investor SR One 2015-12-22
Effector Therapeutics–Novartis: investment, 201512 financing round Series B totalling $40m incl returning investor Novartis Venture Fund 2015-12-22
Effector Therapeutics–SEVERAL: investment, 201512 financing round Series B $40m led by Altitude Life Science Ventures 2015-12-22
Bayer–CRISPR Therapeutics: CRISPR technology, 201512– collab 50/50 joint venture w minimum of $300m r+d investment by Bayer in next 5 years 2015-12-21
Catherex–Amgen: investment, 201512 acquisition 100% for $10.5m upfront cash + milestones + royalties for Imlygic 2015-12-21
CRISPR Therapeutics–Bayer: investment, 201512– acquisition of minority stake for $35m by BLSC in connection with joint venture collaboration 2015-12-21
Sinphar Pharmaceutical–Medigene: EndoTAG-1, 201512–2016 acquisition of all EndoTAG assets by SynCore Biotechnology 2015-12-17
Xeltis–SEVERAL: investment, 201512 financing round Series B extension €3m bringing total Series B to €30m 2015-12-17
CRISPR Therapeutics–French Myopathy Association: gene therapy, 201512 collab onoging with Généthon 2015-12-16
Sophia Genetics–Alychlo: investment, 201512 financing round Series C totalling $15m incl lead investorAlychlo (Marc Coucke) 2015-12-16
Sophia Genetics–SEVERAL: investment, 201512 financing round Series C $15m led by Alychlo (Marc Coucke) 2015-12-16
Boehringer–Sanofi: investment, 201512–201701 acquisition €6.7b of BI consumer healthcare business (ww excl China) by Sanofi 2015-12-15
Chong Kun Dang–Neovacs: IFNalpha Kinoid, 201512– license excl for ROK + supply €1m upfront + €4m milestones + royalties + margin on supply 2015-12-15
Myelo Therapeutics–SEVERAL: investment, 201512 financing round Series B incl VC Fonds Technologie Berlin + ELSA + JSC Valenta + Vladimir Nebolsin 2015-12-15
Neovacs–ActeaVentures: business consulting, 201512 supply service business development advisor for Neovacs license deal w Chong Kun Dang 2015-12-15
Photonis–MasCom: electron multiplier, 201512– supply by MasCom of multipliers for ICP-MS + resale by Photonis USA 2015-12-15
Sanofi–Boehringer: investment, 201512–201701 acquisition €11.4b of Merial animal health business by BI 2015-12-15
BPCE–Novartis: investment, 201512 strategic investment of Novartis Pharma AG in Health for Life Capital Fund increasing available funds to €160m 2015-12-14
Caltech–Thermo Fisher: mass spectrometer, 201512 supply existent new 253 Ultra HR-IRMS at lab of John Eiler 2015-12-14
Complix–Selexis: biological contract manufacturing, 201512– supply SUREtechnology platform to enable production of Alphabody candidate CMX-02 2015-12-14
ETH Zürich–Thermo Fisher: mass spectrometer, 201512 supply existent new 253 Plus 10kV IRMS at lab of Stefano Bernasconi 2015-12-14
Inthera Bioscience–SEVERAL: investment, 201512 seed financing round €3.4m led by MS Ventures incl Aglaia + Novo Seeds + EVA Basel 2015-12-14
NovaPump–SEVERAL: investment, 201512 financing round with bm|t + Sparkasse Jena-Saale-Holzland 2015-12-14
Sanofi–MAB Discovery: therapeutic antibodies, 201512– collab €na developm MAbs against selected Sanofi targets 2015-12-14
Genetrix (ES)–SEVERAL: investment, 201512 rights offering + private placement of Sygnis AG €5.6m with 2.963m new shares €1.9/share 2015-12-10
Basilea–SEVERAL: credit, 201512 senior unsecured convertible bonds CHF200m with coupon of 2.75% per annum due 2022 2015-12-09
Convergence Pharmaceuticals–Evotec: investment, 201512 acquisition of 51% of shares of Panion Ltd 2015-12-09
Wilex–Hopp Group: investment, 201512 investment €1.712m w 930,560 new shares at €1.84/share dievini Hopp BioTech holding 2015-12-09
Wilex–SEVERAL: investment, 201512 investment €815k w 443,124 new shares at €1.84/share to existent shareholders 2015-12-09
BASF–Evogene: herbicides, 201512–201811 collab 3y r+d novel herbicides using Evogene’s computational discovery approach 2015-12-08
Bridgepoint–Kohlberg Kravis Roberts: investment, 201512 acquisition €na of LGC by KKR from Bridgepoint 2015-12-08
Roche–Pieris: cancer immunotherapy, 201512– collab + license ww up to CHF415m + royalties r+d of Anticalin-based drugs against Roche target 2015-12-08
Max Planck–Bruker Corp: mass spectrometry s/w, 201512 supply Prof Baldwin at MPI ICE Jena early user of MetaboScape s/w to mine complex plant genomics 2015-12-07
Roche–SQZ Biotech: cell therapy, 201512– collab over €500m in upfront+milestones plus royalties developm SQZ technology in oncology 2015-12-07
Kuros–Cytos Biotechnology: investment, 201512–201601 reverse merger acquisition CHF160m of Kuros Biosurgery by Cytos to be renamed Kuros Biosciences 2015-12-03
Kuros–Homburger: legal services, 201512 supply service legal advisor w regard to reverse merger acquisition CHF160m of Kuros Biosurgery by Cytos 2015-12-03
Lucigen–Genetrix (ES): genomic reagents, 201512– distribution of Sygnis TruePrime + SunScript RT products for clinical oncology research in US 2015-12-03
Shuwen Biotech–BioNTech: molecular diagnostics, 201512– collab clin developm + excl distribution rights for MammaTyper test in China 2015-12-03
Boehringer–Univ Texas: cancer drugs, 201512– collab discovery therapeutic concepts for pancreatic cancer w MD Anderson Cancer Center 2015-12-02
Ferring–TxCell: T-cell therapy, –201512 collab + excl option to in-license Ovasave for developm + comercialisation 12/15 TxCell RE-ACQUIRED RIGHTS 2015-12-02
Jennewein Biotechnologie–EU (govt): credit, 201512– loan €10m with equity-type transaction under InnovFin scheme from EIB 2015-12-02
Mayflower Bioscience–Genetrix (ES): genomic reagents, 201512– distribution of Sygnis TruePrime + SunScript RT products in US 2015-12-02
Santhera–Homburger: legal services, 201512 supply service Homburger legal advisor for CHF54.8m private placement 2015-12-02
Amcure–Germany (govt): grant, 201512 BMBF research grant €1.9m to advance lead candidate into clinic 2015-12-01
Amcure–MacDougall Biomedical Communications: public relations, 201512 service existent by MacDougall 2015-12-01
Gene Predictis–OTHER: investment, 201512 1st external invesment CHF0.5m by a strategic investor from Swiss healthcare system 2015-12-01
MATURA Consortium–Protagen: personalised medicine, 201512– project member collab research treatment response predictors in rheumatoid arthritis 2015-12-01
next pagenext page 1 2 3 ... 17 18 19 ... 55 56 57  next pagenext page



Advertisement

Picture EBD Group BIO-Europe Spring 2019 BES Wien Partnering Opens 600x60px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

» top